Targeting Macrophage-Mediated Tumor Cell Phagocytosis: An Overview of Phagocytosis Checkpoints Blockade, Nanomedicine Intervention, and Engineered Car-Macrophage Therapy Publisher Pubmed



Moradinasab S¹ ; Pourbagherisigaroodi A² ; Ghaffari SH³ ; Bashash D² Show Affiliations
Source: International Immunopharmacology Published:2022

Abstract

Immunotherapy has been developing at an unprecedented speed with promising therapeutic outcomes in the wide spectrum of cancers. Up until now, most immunotherapies have focused on adaptive immunity; however, investigating the potential of macrophage phagocytosis and consequent adaptive immune cross-priming has led to a growing interest in exploiting macrophages in cancer therapy. In light of the positive evidence from preclinical studies and early clinical data, targeting macrophage phagocytosis has become a promising therapeutic strategy. Here, we review therapies based on harnessing and amplifying macrophage phagocytosis, such as blocking phagocytosis checkpoints and exploiting nanoparticles as efficient approaches in elevating macrophages-mediated phagocytosis. The present study introduces CAR-macrophage as the state-of-the-art modality serving as the bridge between the innate and adaptive immune system to mount a superior anti-tumor response in the treatment of cancer. We also take a look at the recent reports of therapies based on CAR-engineered macrophages with the hope of providing a future research direction for expanding the application of CAR-macrophage therapy. © 2021 Elsevier B.V.